NEW BRUNSWICK, N.J.—Johnson & Johnson (NYSE: JNJ), a global healthcare company, announced its second-quarter 2026 financial results yesterday, reporting a 6.6 percent increase in sales to $25.3 billion. The company achieved 5.6 percent operational growth and 5.7 percent adjusted operational growth. Within the MedTech segment, which saw revenue rise 4.5 percent to $8.9 billion, the vision care category performed strongly, delivering 6 percent reported revenue growth (5.7 percent operationally). The company also raised its full-year 2026 outlook.
“Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world’s toughest health challenges,” said Joaquin Duato, chairman and CEO, Johnson & Johnson. “With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our company’s 140-year history.”
During the second quarter, the company achieved a 7.3 percent revenue increase in the U.S. Meanwhile, international revenue grew by 5.7 percent, contributing to an overall worldwide revenue growth of 6.6 percent.
MedTech worldwide operational sales grew 3.6 percent operationally, primarily driven by wound closure products and biosurgery products in surgery, electrophysiology products and shockwave in cardiovascular, contact lenses in vision, and trauma in orthopedics.
The increase in vision was driven by strong performance of the company’s Acuvue Oasys 1-Day family of products, including recent launches and strategic price actions, the company said. Growth in surgical vision was reported as 4.7 percent, driven by the strength of recent product innovations, demand for premium IOLs, and strong commercial execution, partially offset by competitive pressures in the U.S.
“In vision, we have a bold ambition to make vision possible for more than 40 million people each year,” said Duato on an analyst call. “In Q2, we announced the expanded U.S. availability of Tecnis PureSee, as we accelerate the rollout of this extended depth of focus intraocular lens.”
Joe Wolk, executive vice president, chief financial officer, added on the call that the company expects MedTech sales to accelerate in the second half of 2026. Among the anticipated drivers in vision, Wolk pointed to the company’s Tecnis PureSee IOLs as well as the Acuvue line of contact lenses. “There are several important catalysts we expect to generate momentum in the second half,” he said. “We continue to expand the availability of the Tecnis PureSee lens for cataracts and presbyopia, while also driving the adoption of Acuvue Oasys Max (contact) lenses.”
The company also announced that its Innovative Medicine segment saw worldwide operational sales growth of 6.8 percent in the second quarter. Growth was primarily driven by Darzalex, Carvykti, Tecvayli and Rybrevant/Lazcluze in oncology, Tremfya and other immunology in immunology, and Spravato and Caplyta in neuroscience.
Johnson & Johnson also raised its 2026 full-year guidance. The company now expects full-year revenue in the range of $100.8 billion to $101.4 billion. Last month, the company announced an investment of more than $1 billion in Jacksonville, Fla., to strengthen its vision operations by scaling the U.S.-based manufacturing, packaging and distribution capabilities.
